Zemcelpro
·
- Prescription status not stated
- Blood, clotting and anaemia
- Used in
- Blood, clotting and anaemia
- Made by
- Cordex Biologics International Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Treatment of adult patients with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following myeloablative conditioning for whom no other type of suitable donor cells is available
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
NetherlandsNo exact match for this strength and form
Details
| Made by | Cordex Biologics International Limited |
|---|---|
| Active substance | Allogeneic umbilical cord-derived CD34- cells, non-expanded;dorocubicel |
| Used in | Blood, clotting and anaemia |
| Classification | B05AX04 · Blood, clotting and anaemia |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2025-08-25 |
| Last updated by the regulator | 2026-07-16 |
| EMA product number | EMEA/H/C/005772 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).